Despite the FDA's announcement that it would miss the January 16 deadline for its ruling on MannKind's inhaled insulin drug Afrezza, CEO Alfred Mann is still confident that an approval will arrive in short order. The agency says it needs more time to complete its inspection of an insulin manufacturing facilities. "My guess is an action letter will come within days of the inspection," Mann said at the J.P. Morgan healthcare conference, as reported in Reuters. "We have nothing from our side that's due." Article